Mustang Bio, Inc. (MBIO)

Market Cap	3.43M
Revenue (ttm)	n/a
Net Income (ttm)	-51.60M
Shares Out	10.39M
EPS (ttm)	-6.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,997
Open	0.361
Previous Close	0.358
Day's Range	0.320 - 0.370
52-Week Range	0.320 - 8.170
Beta	1.54
Analysts	Strong Buy
Price Target	19.67 (+5,982.25%)
Earnings Date	May 10, 2024

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare g...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Manuel Litchman M.D.
• Employees: 80
• Stock Exchange: NASDAQ
• Ticker Symbol: MBIO

Analyst Forecast

According to 3 analysts, the average rating for MBIO stock is "Strong Buy." The 12-month stock price forecast is $19.67, which is an increase of 5,982.25% from the latest price.

Price Target

$19.67

(5,982.25% upside)

Analyst Consensus: Strong Buy